Press Releases

SUZHOU, China, Dec. 9, 2019 /PRNewswire/ -- CStone Pharmaceuticals ("CStone" or the "Company", HKEX: 2616) updated results from the CS1001-201 trial in a poster presentation at the 2019 American Society of Hematology (ASH) Annual Meeting. CS1001-201 trial is a single-arm, multicenter Phase II clinical study designed to evaluate CS1001 monotherapy in relapsed or re

WASHINGTON, Dec. 9, 2019 /PRNewswire/ -- Following the release of details from a surprise billing agreement between Senate Health, Education, Labor and Pensions (HELP) Committee Chairman Lamar Alexander (R-TN) and House Energy and Commerce Committee Chairman Frank Pallone Jr. (D-NJ) and Ranking Member Greg Wal

MANHASSET, N.Y., Dec. 9, 2019 /PRNewswire/ -- A team led by Stavros Zanos, MD,

ATLANTA, Dec. 9, 2019 /PRNewswire/ -- UCB, a global biopharmaceutical company, today announced positive results from a Phase II study (TP0001; NCT02718716) of its novel, first-in-class subcutaneous (SC, under the skin) monoclonal antibody, rozanolixizumab, in patients with primary immune thrombocytopenia (ITP). The data were presented during an oral presentation tod

TOLEDO, Ohio, Dec. 9, 2019 /PRNewswire/ -- Welltower Inc. (NYSE: WELL) announces that on December 24, 2019, it is redeeming all of the outstanding 3.35% Senior Notes due November 25, 2020 (the "Notes") issued by HCN Canadian Holdings-1 LP, its wholly-owned subsidiary, in accordance with the terms of the Not

SECAUCUS, N.J., Dec. 9, 2019 /PRNewswire/ -- Quest Diagnostics Incorporated (NYSE: DGX), the world's leading provider of diagnostic information services, announced today the pricing of a public offering of $800 million aggregate principal amount of its 2.950% senior notes due 2030 under the Quest Diagnostics' shelf registration statement. 

MIAMI, Dec. 9, 2019 /PRNewswire/ -- Florida International University Distinguished Professor Madhavan Nair has been named a Fellow of the

ORLANDO, Fla., Dec. 9, 2019 /PRNewswire/ -- The Janssen Pharmaceutical Companies of Johnson & Johnson announced today overall survival (OS) results from the Phase 3 ALCYONE study (

SAN FRANCISCO, Dec. 9, 2019 /PRNewswire/ -- On Lok and

NEWARK, N.J., Dec. 9, 2019 /PRNewswire/ -- Rafael Holdings, Inc., (NYSE: RFL), reported revenue of $1.2 million and a loss per share of $0.10 for the fiscal quarter ended October 31, 2019.